Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2009

EraGen and Illumina Enter Cross-Licensing Deal for Molecular Diagnostics

  • EraGen Biosciences and Illumina are combining technologies to advance molecular diagnostic offerings. EraGen Biosciences will have access to Illumina’s BeadXpress platform for the development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its own MultiCode®-PLx technology. Illumina has licensed EraGen’s MultiCode-PLx platform for the life sciences, research, and clinical markets.


Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »